Anti-cancer properties of Sansalvamide A, its derivatives, and analogs: an updated review
Por:
Chagaleti B.K., Baby K., Peña-Corona S.I., Leyva-Gómez G., S. M S., Naveen N.R., Jose J., Aldahish A.A., Sharifi-Rad J., Calina D.
Publicada:
1 ene 2024
Ahead of Print:
1 may 2024
Resumen:
As peptide-based therapies gain recognition for their potential anti-cancer activity, cyclic peptides like Sansalvamide A, a marine-derived cyclic depsipeptide, have emerged as a potential anti-cancer agent due to their potent activity against various cancer types in preclinical studies. This review offers a comprehensive overview of Sansalvamide A, including its sources, structure–activity relationship, and semi-synthetic derivatives. The review also aims to outline the mechanisms through which Sansalvamide A and its analogs exert their anti-proliferative effects and to discuss the need for enhancements in pharmacokinetic profiles for better clinical utility. An extensive literature search was conducted, focusing on studies that detailed the anti-cancer activity of Sansalvamide A, its pharmacokinetics, and mechanistic pathways. Data from both in vitro and in vivo studies were collated and analyzed. Sansalvamide A and its analogs demonstrated significant anti-cancer activity across various cancer models, mediated through Hsp 90 inhibition, Topoisomerase inhibition, and G0/G1 cell cycle arrest. However, their pharmacokinetic properties were identified as a significant limitation, requiring improvement for effective clinical translation. Despite its notable anti-cancer effects, the utility of Sansalvamide A is currently limited by its pharmacokinetic characteristics. Therefore, while Sansalvamide A exhibits promise as an anti-cancer agent, there is a compelling need for further clinical and toxicological studies and optimization of its pharmacokinetic profile to fully exploit its therapeutic potential alongside modern cancer therapies. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.
Filiaciones:
Chagaleti B.K.:
Department of Pharmaceutical Chemistry, Akshaya Institute of Pharmacy, Karnataka, Tumkur, India
Baby K.:
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
Peña-Corona S.I.:
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Mexico, Mexico
Leyva-Gómez G.:
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Mexico, Mexico
S. M S.:
Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Karnataka, Mangaluru, 575018, India
Naveen N.R.:
Department of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagar, Karnataka, Bellur, India
Jose J.:
Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Karnataka, Mangaluru, 575018, India
Aldahish A.A.:
Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, 61441, Saudi Arabia
Sharifi-Rad J.:
Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador
Calina D.:
Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania
|